Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 6/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697493 | 1.00 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTNFKB1 | |
| SCHEMBL5722322 | 1.00 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTNFKB1 | |
| SCHEMBL9135070 | 1.00 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTNFKB1 | |
| SCHEMBL30839518 | 1.00 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Bromide SCHEMBL354391 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Hydrochloric Acid SCHEMBL9317222 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Water SCHEMBL9305270 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Water SCHEMBL9305264 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Bromide SCHEMBL5722309 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 | |
| Bromide SCHEMBL354286 | 0.98 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108455563-A | A kind of preparation method of Nitrogen-rich porous carbon microballoon | 天津工业大学 | 2018-08-28 | — | — | CN | claimed |
| EP-0347313-B1 | 2-Amino-7-hydroxytetraline ethers | SANOFI ELF (FR) | 1993-12-15 | — | — | EP | claimed |
| EP-0383686-B1 | 2-AMINO-7-HYDROXYTETRALINE CARBOXYALKYL ETHERS | ELF SANOFI (FR) | 1993-08-04 | — | — | EP | claimed |
| US-5202466-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1993-04-13 | — | — | US | claimed |
| US-5198586-A | Process for the preparation of phenylethanolaminotetralins | SANOFI (FR) | 1993-03-30 | — | — | US | claimed |
| US-5159103-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1992-10-27 | — | — | US | claimed |
| EP-0303545-B1 | PROCESS FOR THE PREPARATION OF PHENYLETHANOLAMINOTETRALINES | ELF SANOFI (FR) | 1992-06-17 | — | — | EP | claimed |
| EP-0383686-A1 | 2-Amino-7-hydroxytetraline carboxyalkyl ethers | ELF SANOFI (FR) | 1990-08-22 | — | — | EP | claimed |
| EP-0347313-A2 | 2-Amino-7-hydroxytetraline ethers | ELF SANOFI (FR) | 1989-12-20 | — | — | EP | claimed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | claimed |
| JP-2196760-A | — | — | None | — | — | JP | disclosed |
| US-11970512-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-30 | — | — | US | disclosed |
| CN-110407898-B | Amphotericin B derivatives with improved therapeutic index | 伊利诺伊大学评议会 | 2023-12-01 | — | — | CN | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-0347313-A2 | 2-Amino-7-hydroxytetraline ethers | ELF SANOFI (FR) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989009050-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1989-10-05 | — | — | WO | disclosed |
| EP-0334538-A1 | Therapeutically useful tetralin derivatives | THE UPJOHN COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | DRD2 1634/4885DRD3 1688/4885OPRK1 176/4885 |
| US-11970512-B2 | Amphotericin B derivatives with improved therapeutic index | C9, AMPD3, C5 | DRD2 4145/4885DRD3 2361/4885OPRK1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.